C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Hold" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given a consensus rating of "Hold" by the six research firms that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $10.00.

A number of research analysts have weighed in on CCCC shares. BMO Capital Markets reissued an "outperform" rating and set a $20.00 target price on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Stephens started coverage on C4 Therapeutics in a research note on Monday, November 18th. They set an "equal weight" rating and a $4.00 target price for the company.

Institutional Investors Weigh In On C4 Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its position in shares of C4 Therapeutics by 38.4% in the 3rd quarter. Barclays PLC now owns 243,457 shares of the company's stock worth $1,387,000 after purchasing an additional 67,546 shares during the last quarter. Geode Capital Management LLC boosted its holdings in C4 Therapeutics by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,369,676 shares of the company's stock worth $7,809,000 after buying an additional 7,460 shares during the last quarter. Vestcor Inc bought a new stake in shares of C4 Therapeutics in the 3rd quarter valued at about $168,000. M&T Bank Corp increased its stake in shares of C4 Therapeutics by 19.3% in the 3rd quarter. M&T Bank Corp now owns 113,907 shares of the company's stock valued at $649,000 after acquiring an additional 18,466 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of C4 Therapeutics in the 3rd quarter valued at approximately $484,000. Institutional investors own 78.81% of the company's stock.

C4 Therapeutics Stock Performance

Shares of CCCC traded up $0.13 during trading hours on Monday, hitting $4.38. 829,873 shares of the company were exchanged, compared to its average volume of 2,102,378. The firm's 50 day moving average is $5.68 and its 200-day moving average is $5.63. C4 Therapeutics has a 52 week low of $1.06 and a 52 week high of $11.88.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The company had revenue of $15.36 million for the quarter, compared to the consensus estimate of $5.95 million. As a group, equities research analysts forecast that C4 Therapeutics will post -1.48 earnings per share for the current fiscal year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.